FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

The FDA issued a warning letter to ProRx, a compounding facility in Exton, Penn., after an inspection raised serious concerns regarding the safety and compliance of its drug products. The facility, ...

Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

With tirzepatide and its Novo Nordisk rival ... Late last month, Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said in a statement that the FDA decision was “not necessarily ...

In its petition, Novo Nordisk says that the Outsourcing Facilities Association (OFA), a trade organisation representing the compounding pharmacy ... making copies of tirzepatide, its GLP-1 and ...

tirzepatide. The FDA declined to comment. The Outsourcing Facilities Association, which brought the lawsuit along with a Texas compounding pharmacy did not immediately respond to requests for comment.

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade ... s reaffirmation, 503B compounding pharmacies have until March 19 to stop selling compounded tirzepatide. In its motion filed ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

Dr. George Carroll runs BeSlimMD, a private weight loss clinic in Maitland. He has been helping patients lose weight for more ...